To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC).
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
VENTURINI, SERGIO;
2015-01-01
Abstract
To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC).
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Venturini_13.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
836.55 kB
Formato
Adobe PDF
|
836.55 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
